The company attaches great importance to the construction of scientific research team and R&D platform. We have nearly one hundred professional technicians and technical platforms for enzyme immunoassay, chemiluminescence, rapid diagnosis, nucleic acid diagnosis, virus isolation and large-scale culture, genetic engineering, monoclonal antibody and polyclonal antibody preparation, and large-scale purification. The company also attaches great importance to cooperation and academic exchanges with research institutes. We maintain a long-term and stable cooperative relationship with Xiamen University, and have established teaching bases with Beijing Normal University, Shenyang Pharmaceutical University and four other universities***, which greatly improves the company's technical level and scientific research strength.
The company has undertaken a number of scientific research projects such as the National 863 Program, the Ninth Five-Year Plan, the Fifteenth Five-Year Plan, the Eleventh Five-Year Plan, the Twelfth Five-Year Plan and the Twelfth Five-Year Plan for Major Infectious Diseases, and the Ministry of Education, the provincial (municipal) key projects, etc., which has facilitated the rapid transformation of the scientific research results and their industrialization.In 2008, the company was awarded the "National High-technology Industrialization Ten-Year Achievement Award".
Beijing Wantai has more than 30 provincial level agents and more than 300 secondary agents, establishing a marketing network with distinct levels and nationwide coverage. High-quality products and successful marketing strategy make Beijing Wantai's products keep the first place in the share of blood stations for many years, and the clinical market share is also among the top. Beijing Wantai's products are sold to more than 30 countries such as the United States, Britain, Germany, Spain, Indonesia, Iran, India, Brazil, South Africa and so on, and the high quality products have been widely praised by foreign customers.
Introducing advanced technology, serving the Chinese market, we are committed to building Beijing Wantai into a biomedical high-tech industry with international advanced level. The company maintains close contact with WHO (World Health Organization), ISBT (International Society of Blood Transfusion) and other international organizations, and regularly participates in the annual meeting of AACC (American Association of Clinical Chemistry), MEDICA (International Hospital and Medical Equipment Exhibition) and other large-scale international academic conferences and exhibitions. We have also established good cooperative relationships with world-renowned companies such as BIO-RAD (USA) and Diagast (France). We have reason to believe that under the unremitting efforts of a group of domestic famous biopharmaceutical enterprises represented by Beijing Wantai, China's biotechnology industry will rapidly grow into a giant commensurate with its international status!